Neuromodulation therapy is vigorously proven to support treatments of various neurological, chronic and mental diseases and disorders. This includes, but is NOT limited to:
Get your life back with SOZO
Depression is a common mental disorder characterized by persistent sadness and a loss of interest in activities that are typically enjoyable. This tends to lead to an inability to carry out daily activities, erratic sleep habits, loss of appetite (or increased appetite with atypical depression), constant fatigue, etc. It can significantly impair social, occupational, and daily functioning.
Neurophysiology of Disease/Disorder:
Depression involves dysfunction in multiple brain systems:
Depression affects over 280 million people worldwide (WHO estimate), with a lifetime prevalence of about 15–20%. It is more common in women, often emerging in adolescence or early adulthood, and can be recurrent or chronic.
Neuromodulation is transforming how we approach depression—offering a safe, effective, and drug-free solution for individuals who haven’t fully responded to conventional therapies. Backed by clinical research, neuromodulation consistently delivers meaningful symptom relief in 25% to 50% of patients, with up to 40% achieving significant improvement.
Effect of Neuromodulation:
Neuromodulation helps reverse core physiological changes in depression by restoring cortical activity, enhancing connectivity and neuroplasticity, and modulating neurotransmitter systems. This multi-level impact makes it a promising adjunctive treatment, particularly in patients with disrupted brain network function.
Non-invasive neuromodulation using tDCS and CES
Migraine is a neurological disorder characterized by recurrent attacks of moderate to severe headache, often accompanied by nausea, light and sound sensitivity, and in some cases, visual or sensory disturbances (aura). It is more than just a headache—it’s a disabling condition that disrupts quality of life, productivity, and daily functioning.
Neurophysiology of Disease/Disorder:
Migraine involves complex dysfunction in both vascular and neural systems, including:
Migraine affects over 1 billion people globally, making it the third most prevalent disorder and the second leading cause of disability worldwide (Global Burden of Disease Study). It is more common in women, with peak onset between ages 15 and 49, and can be episodic or chronic.
Neuromodulation is emerging as a breakthrough, non-pharmaceutical solution for migraine sufferers—especially those who don’t respond well to medications or prefer to avoid systemic treatments. Clinical research shows Neuromodulation can reduce migraine frequency by 20–60%, shorten attack duration, and lower medication use. In some studies, 60% of patients report a ≥50% reduction in headache days after applying non-invasive neuromodulation protocols in their daily routines.
Neuromodulation can be used prophylactically (to prevent attacks) or acutely (at onset), depending on the modality and protocol.
Effect of Neuromodulation:
Neuromodulation targets dysregulated neural pathways and hyperexcitable cortical networks that underlie migraine. It helps to:
These physiological effects position neuromodulation as a highly promising adjunct or alternative to medication—non-invasive, drug-free, and clinically proven to reduce the burden of migraine.
Non-invasive neuromodulation using tDCS and CES.
Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive dysfunction, and heightened sensitivity to touch and pressure. As a pain disorder it involves a deeper imbalance in how the central nervous system processes sensory information.
Neurophysiology of Disease/Disorder:
Fibromyalgia is associated with central sensitization, a state where the nervous system becomes hypersensitive to pain and sensory input.
Key physiological features include:
Fibromyalgia affects an estimated 2–4% of the global population, with a significantly higher prevalence in women. It typically emerges in adulthood and is frequently comorbid with depression, anxiety, and other chronic conditions. The disorder is debilitating, often reducing work capacity and quality of life.
Neuromodulation offers a drug-free approach for managing fibromyalgia, especially in patients with limited relief from medications. Clinical studies demonstrate that neuromodulation can lead to pain reduction of 33–60%, improved sleep quality, better mood, and enhanced cognitive function. Some trials report response rates above 40% after consistent use.
Effect of Neuromodulation:
Neuromodulation targets the dysregulated brain circuits involved in pain amplification, emotional regulation, and cognitive clarity. It helps to:
This multifaceted effect makes neuromodulation a powerful adjunct or alternative to pharmacological treatment. It is safe, accessible, and personalized for long-term symptom management in fibromyalgia.
Non-invasive neuromodulation using tDCS and CES.
Failed Back Surgery Syndrome (FBSS) is a chronic pain condition that persists or worsens after spinal surgery. Despite technically successful procedures, patients continue to experience debilitating back and/or leg pain, often accompanied by numbness, muscle weakness, and functional impairment. FBSS reflects not just mechanical issues, but a complex failure of the nervous system to properly regulate pain.
Neurophysiology of Disease/Disorder:
The pain in FBSS stems from a combination of peripheral nerve injury, spinal pathology, and central sensitization. Key mechanisms include:
Estimates of the percentage of adults who experience chronic lower back pain during their lifetime range from 51% to 84%. FBSS is reported to affect between 10 to 40% of patients following back surgery. Increased complexity of back surgery increases the rate of FBSS; failure rates range from 30% to 46% for lumbar fusion and 19% to 25% for microdiscectomy.
It is a leading cause of chronic disability and opioid dependence, with a significant impact on mobility, mental health, and quality of life.
Clinical research has shown that neuromodulation can achieve pain reductions of 60-75%, even in long-standing, treatment-resistant cases. Improvements have also been noted in mobility, mood, and medication reduction, especially in patients with a strong neuropathic component to their pain.
Effect of Neuromodulation:
Neuromodulation targets the maladaptive changes in the brain and spinal cord associated with FBSS. It helps to:
Non-invasive neuromodulation using a combination of tDCS and CES.
Chronic post-surgery pain is an unwanted adverse event in any operation and either manifests itself or becomes more intense, even after the healing process which is usually 3 months. Chronic post-operative pain is one of the most common complications of surgery.
Prevalence of chronic pain among adults ranges from 20.5% to 21.8% and the prevalence of high-impact chronic pain ranges from 6.9% to 7.8%.
Non-invasive neuromodulation using a combination of taVNS and tDCS.
Anxiety disorders are characterized by excessive fear and worry and related behavioral disturbances. There are several different kinds of anxiety disorders, such as: generalized anxiety disorder (characterized by excessive worry), panic disorder (characterized by panic attacks), social anxiety disorder (characterized by excessive fear and worry in social situations), separation anxiety disorder (characterized by excessive fear or anxiety about separation from those individuals to whom the person has a deep emotional bond), and others.
An estimated 4.05% of the global population has an anxiety disorder, translating to 301 million people. The number of persons affected has increased by more than 55% from 1990 to 2021.
Non-invasive neuromodulation using a combination of taVNS and tDCS.
Bipolar disorder is a mental health condition with extreme mood swings, from emotional highs (you feel euphoric, energized, or excessively irritable) to extreme opposite lows (you could feel melancholy or hopeless and stop enjoying or being interested in most activities). Episodes of mood swings may occur rarely or multiple times a year. While most people will experience some emotional symptoms between episodes, some may not experience any.
In 2019, 40 million people experienced bipolar disorder
Non-invasive neuromodulation using tDCS.
Insomnia is a sleep disorder that can make it difficult to get asleep, keep asleep, or lead you to wake up too early and have trouble falling back asleep. This disorder could negatively affect your health, productivity at work, and quality of life in addition to your energy level and mood.
Chronic insomnia is highly prevalent and affects approximately 30% of the general population.
Non-invasive neuromodulation using a combination of taVNS and tDCS.
A horrific event can cause post-traumatic stress disorder (PTSD), a mental health disease that can be brought on by experiencing it or seeing it. Flashbacks, nightmares, excruciating anxiety, and uncontrollable thoughts about the incident are just a few possible symptoms.
Moderate quality evidence finds the lifetime worldwide prevalence of PTSD in the general population is around 3.9%. In people known to have been exposed to trauma, the rate is 5.6%.
Non-invasive neuromodulation using a combination of taVNS and tDCS.
Parkinson’s disease is a chronic condition that affects both the neurological system and the body parts that are under the control of the nervous system. Symptoms emerge gradually, while the initial sign could be a slight tremor in just one hand. Tremors are common, but the disorder may also cause stiffness or slowing of movement.
More than 10 million people worldwide are living with PD. The increases with age, but an estimated four percent of people with PD are diagnosed before age 50.
Non-invasive neuromodulation using a combination of taVNS and tDCS.
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerve fibers.
The estimated number of people with MS worldwide has increased to 2.8 million in 2020.
Non-invasive neuromodulation using tDCS.
Learning Disabilities affect the ability to comprehend, or use spoken or written language, perform mathematical computations, coordinate motions, or focus attention. Even though they can affect very young children, learning problems are typically not identified until the kid is of school age.
The estimate for current learning disabilities among children of ages 3–17 years is 7.8 %, with 3.7 % rated as mild and 4.0 % rated as moderate or severe. Approximately 1,7 % of adults experience learning disabilities.
Non-invasive neuromodulation using tDCS.
Irritable bowel syndrome (IBS) is a common disorder that affects the stomach and intestines, also called the gastrointestinal tract. Symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that you’ll need to manage long term.
Irritable bowel syndrome affects approximately 10-15% of the European population.
Non-invasive neuromodulation using a combination of taVNS and tDCS.
Mild cognitive impairment (MCI) is the stage between the expected decline in memory and thinking that happens with age and the more serious decline of dementia. MCI may include problems with memory, language or judgment.
The overall prevalence of MCI is 15.56% worldwide in adults aged 50 years and older. Prevalence rates of amnestic MCI and non-amnestic MCI is 10.03% and 8.72%.
Non-invasive neuromodulation using tDCS.
Addiction is a compulsive, ongoing, physiological or psychological urge for a habit-forming substance, action, or activity that has negative physical, psychological, or social impacts and usually results in well-defined withdrawal or abstinence symptoms such as anxiety, irritability, tremors, or nausea.
Non-invasive neuromodulation using a combination of taVNS and tDCS.
In most cases cancer pain is caused by the physical damage of some certain structures (tumor pressing on bones, nerves or other organs in the body). Sometimes pain may be due to cancer treatment (some chemotherapy drugs, x-ray therapy).
There are different variants of cancer pain: nerve pain, bone pain, soft tissue pain, phantom pain, referred pain.
Variants of treatment: medications, procedures to block pain signal, integrative therapies.
Non-invasive neuromodulation using a combination of taVNS and tDCS.
ADHD include inattention (not being able to keep focus), hyperactivity (excess movement that is not fitting to the setting) and impulsivity (hasty acts that occur in the moment without thought).
ADHD include inattention (not being able to keep focus), hyperactivity (excess movement that is not fitting to the setting) and impulsivity (hasty acts that occur in the moment without thought).
Non-invasive neuromodulation using tDCS.
ALS is a progressive neurological disorder that affects nerve cells in the brain and spinal cord. This leads to the gradual loss of motor neurons, causing muscle weakness, difficulty speaking, swallowing, and eventually breathing. Over time, the ability to control voluntary movements is completely lost, while cognitive function may remain intact in most patients.
ALS is a rare disease, with an estimated prevalence of 4-8 per 100,000 people globally as of 2024. The condition typically affects people between the ages of 40 and 70, with men slightly more affected than women. While the exact cause remains unknown, genetic and environmental factors are believed to play a role.
Dementia is a decline in cognitive abilities that interferes with daily life, often caused by Alzheimer’s disease.
Dementia affects 5–8% of people over 60 worldwide.
Among neuromodulation therapies, repetitive Transcranial Pulse Stimulation (TPS) has shown the most promise in enhancing cognition and slowing progression, especially in early stages. With even higher efficacy in combination with tDCS.
Alzheimer’s is the most common form of dementia, marked by memory loss, confusion, and behavioral changes.
Alzheimer’s is affecting 6–7% of people over 60 on a global scale.
TPS is currently the most effective neuromodulation option for improving function and delaying symptoms in early to moderate stages.
Neurodevelopmental disorders (NDDs) are a group of conditions resulting from atypical brain development, typically emerging in early childhood and affecting cognition, behavior, emotion, and social functioning. These include Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), intellectual disabilities, communication disorders, and specific learning disorders. Common features across NDDs include deficits in executive function, attention regulation, adaptive behavior, and social-emotional skills. These conditions often co-occur and persist across the lifespan, requiring long-term, individualized support.
ASD is a prominent example, characterized by difficulties in social interaction, communication, and the presence of restricted, repetitive behaviors. However, each NDD has unique clinical profiles and underlying neural mechanisms.
Neurodevelopmental disorders affect an estimated 15–20% of children globally. ASD is diagnosed in approximately 1–2% of individuals worldwide, while ADHD affects 5–7% of school-aged children. Many individuals experience comorbid symptoms across multiple domains. The impact on education, employment, mental health, and family systems is substantial, highlighting the need for early and effective interventions.
Neuromodulation methods are promising adjunctive interventions for NDDs, targeting cortical regions involved in attention, emotion, and cognitive control. Studies show modest but meaningful improvements (15–30%) in attention, working memory, mood regulation, and social behavior, particularly in ASD and ADHD. Various neuromodulation methods may also enhance neuroplasticity, connectivity, and cognitive performance with high spatial precision.
Effect of Neuromodulation:
Neuromodulation techniques modulate brain activity and network dynamics.
Reported effects in NDDs include:
Neuromodulation is not a standalone cure but shows promise as a tool to optimize brain function and amplify the effects of existing therapies in children and adults with NDDs.
Book a consultation today to learn more about how neuromodulation therapy can help.
